AR110800A1 - MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA - Google Patents
MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASAInfo
- Publication number
- AR110800A1 AR110800A1 ARP180100341A ARP180100341A AR110800A1 AR 110800 A1 AR110800 A1 AR 110800A1 AR P180100341 A ARP180100341 A AR P180100341A AR P180100341 A ARP180100341 A AR P180100341A AR 110800 A1 AR110800 A1 AR 110800A1
- Authority
- AR
- Argentina
- Prior art keywords
- durd
- methods
- inhibition
- mthf
- human
- Prior art date
Links
- 108010022394 Threonine synthase Proteins 0.000 title abstract 6
- 102000005497 Thymidylate Synthase Human genes 0.000 title abstract 6
- 230000005764 inhibitory process Effects 0.000 title abstract 4
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 title 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 title 1
- 210000002381 plasma Anatomy 0.000 title 1
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 abstract 5
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 230000036470 plasma concentration Effects 0.000 abstract 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 2
- 229960002949 fluorouracil Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 229960000397 bevacizumab Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Métodos para aumentar los niveles en plasma de dUrd, dichos métodos comprenden la administración de 6R-MTHF. Los métodos para aumentar dUrd en plasma, aumentan los niveles de dUrd comparados con las concentraciones equimolares de LV. Métodos para aumentar la inhibición de la TS que comprende la administración de 6R-MTHF. Métodos para aumentar la inhibición de la TS, dichos métodos comprenden la administración de 6R-MTHF. Reivindicación 1: Un método para aumentar la concentración en plasma de dUrd en un ser humano caracterizado porque comprende: a) un paso de administrar a dicho ser humano por la vía intravenosa una composición farmacéutica que comprende 6R-MTHF a una dosis de 5 - 1000 mg/m² en combinación con una cantidad terapéuticamente eficaz de, al menos, un agente anticancerígeno; donde dicha administración produce una concentración aumentada en plasma de dUrd. Reivindicación 8: El método de la reivindicación 7, caracterizado porque el compuesto anticancerígeno adicional se selecciona del grupo formado por oxaliplatino, irinotecán y bevacizumab. Reivindicación 9: Un método para inhibir la timidilato sintasa (TS) en un ser humano, dicho método está caracterizado porque comprende: a) un paso de administrar por la vía intravenosa a dicho ser humano una composición farmacéutica que comprende 6R-MTHF a una dosis de 5 - 1000 mg/m² en combinación con una cantidad terapéuticamente eficaz de, al menos, un agente anticancerígeno; caracterizado porque dicha administración produce una inhibición aumentada de la TS con respecto a un ser humano que recibe una dosis equimolar de LV. Reivindicación 13: El método de la reivindicación 9, caracterizado porque el, como mínimo un agente anticancerígeno es 5-flurouracil (5-FU).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762458868P | 2017-02-14 | 2017-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110800A1 true AR110800A1 (es) | 2019-05-02 |
Family
ID=62002152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100341A AR110800A1 (es) | 2017-02-14 | 2018-02-14 | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA |
Country Status (15)
Country | Link |
---|---|
US (3) | US10292984B2 (es) |
EP (2) | EP3848036A3 (es) |
JP (2) | JP7122256B2 (es) |
KR (1) | KR20190112711A (es) |
CN (1) | CN110430896A (es) |
AR (1) | AR110800A1 (es) |
AU (1) | AU2018220861B2 (es) |
BR (1) | BR112019016668A2 (es) |
CA (1) | CA3053293C (es) |
IL (1) | IL268439B2 (es) |
MX (1) | MX2019009610A (es) |
PH (1) | PH12019501893A1 (es) |
SG (1) | SG11201907442UA (es) |
TW (1) | TWI803480B (es) |
WO (1) | WO2018150264A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3848036A3 (en) * | 2017-02-14 | 2021-08-18 | Isofol Medical AB | Methods for increasing blood plasma 2'-deoxyuridine (durd) and thymidylate synthase inhibition |
WO2023046307A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
WO2023046305A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer |
WO2023046304A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
CN114910579B (zh) * | 2022-04-13 | 2023-04-07 | 中国药科大学 | 血清中脱氧尿苷定量测定方法及在心肌梗死诊断中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376658A (en) * | 1990-05-11 | 1994-12-27 | University Of Southern California | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
KR20070019725A (ko) | 2004-04-02 | 2007-02-15 | 어드벤트륵스 파마슈티칼스, 인크. | 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도 |
CN1942189A (zh) * | 2004-04-02 | 2007-04-04 | 阿德文特克斯药物有限公司 | 5,10-亚甲基四氢叶酸在癌症治疗中的用途 |
EP1740182A2 (en) * | 2004-04-02 | 2007-01-10 | M. Robbins Joan | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
KR20080074201A (ko) | 2005-12-02 | 2008-08-12 | 어드벤트륵스 파마슈티칼스, 인크. | 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물 |
RU2492864C2 (ru) * | 2006-09-18 | 2013-09-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения рака, несущего мутации egfr |
WO2008109349A1 (en) | 2007-03-06 | 2008-09-12 | Adventrx Pharmaceuticals, Inc. | Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine |
CA2738753C (en) * | 2008-09-26 | 2018-11-06 | Universite D'angers | Individual 5-fluorouracile dose optimization in folfox treatment |
US20120207671A1 (en) * | 2010-04-15 | 2012-08-16 | Vegenics Pty Limited | Combination treatment with vegf-c antagonists |
EP2617421A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
EP2617422A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
WO2018065446A1 (en) * | 2016-10-05 | 2018-04-12 | Isofol Medical Ab | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
WO2018065445A1 (en) * | 2016-10-05 | 2018-04-12 | Isofol Medical Ab | [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
EP3305318A1 (en) * | 2016-10-05 | 2018-04-11 | Isofol Medical AB | [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy |
EP3446703A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
EP3848036A3 (en) * | 2017-02-14 | 2021-08-18 | Isofol Medical AB | Methods for increasing blood plasma 2'-deoxyuridine (durd) and thymidylate synthase inhibition |
-
2018
- 2018-02-09 EP EP21160188.5A patent/EP3848036A3/en active Pending
- 2018-02-09 US US15/893,235 patent/US10292984B2/en active Active
- 2018-02-09 WO PCT/IB2018/000206 patent/WO2018150264A1/en unknown
- 2018-02-09 BR BR112019016668A patent/BR112019016668A2/pt unknown
- 2018-02-09 IL IL268439A patent/IL268439B2/en unknown
- 2018-02-09 CN CN201880011281.7A patent/CN110430896A/zh active Pending
- 2018-02-09 SG SG11201907442UA patent/SG11201907442UA/en unknown
- 2018-02-09 EP EP18718182.1A patent/EP3582812A1/en active Pending
- 2018-02-09 JP JP2018557782A patent/JP7122256B2/ja active Active
- 2018-02-09 AU AU2018220861A patent/AU2018220861B2/en active Active
- 2018-02-09 CA CA3053293A patent/CA3053293C/en active Active
- 2018-02-09 MX MX2019009610A patent/MX2019009610A/es unknown
- 2018-02-09 KR KR1020197001570A patent/KR20190112711A/ko not_active IP Right Cessation
- 2018-02-12 TW TW107105053A patent/TWI803480B/zh active
- 2018-02-14 AR ARP180100341A patent/AR110800A1/es unknown
-
2019
- 2019-02-04 US US16/266,960 patent/US10639311B2/en active Active
- 2019-08-14 PH PH12019501893A patent/PH12019501893A1/en unknown
-
2020
- 2020-05-04 US US16/866,276 patent/US11389452B2/en active Active
- 2020-10-09 JP JP2020171076A patent/JP2021008510A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020505316A (ja) | 2020-02-20 |
SG11201907442UA (en) | 2019-09-27 |
KR20190112711A (ko) | 2019-10-07 |
CA3053293A1 (en) | 2018-08-23 |
US20180289711A1 (en) | 2018-10-11 |
US11389452B2 (en) | 2022-07-19 |
AU2018220861A1 (en) | 2019-09-05 |
MX2019009610A (es) | 2020-01-14 |
PH12019501893A1 (en) | 2019-10-21 |
IL268439B1 (en) | 2023-12-01 |
RU2019126648A3 (es) | 2021-03-16 |
NZ756408A (en) | 2024-01-26 |
RU2019126648A (ru) | 2021-03-16 |
EP3582812A1 (en) | 2019-12-25 |
US20190240224A1 (en) | 2019-08-08 |
JP7122256B2 (ja) | 2022-08-19 |
IL268439A (en) | 2019-09-26 |
BR112019016668A2 (pt) | 2020-04-07 |
AU2018220861B2 (en) | 2021-08-19 |
TWI803480B (zh) | 2023-06-01 |
EP3848036A3 (en) | 2021-08-18 |
US10639311B2 (en) | 2020-05-05 |
WO2018150264A1 (en) | 2018-08-23 |
US10292984B2 (en) | 2019-05-21 |
TW201832766A (zh) | 2018-09-16 |
JP2021008510A (ja) | 2021-01-28 |
US20200330468A1 (en) | 2020-10-22 |
IL268439B2 (en) | 2024-04-01 |
CA3053293C (en) | 2023-01-03 |
EP3848036A2 (en) | 2021-07-14 |
CN110430896A (zh) | 2019-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
RU2017134443A (ru) | Способ лечения с применением традипитанта | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
CL2022000875A1 (es) | Inhibidores del factor d del complemento para administración oral | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
ECSP22036455A (es) | Inhibidores del factor d del complemento para administraci?n oral | |
BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
CO2020000529A2 (es) | Metodos para tratar hiperinsulinismo congenito | |
UY38948A (es) | Régimen de dosificación para agentes anti-dll3 | |
MX2021004138A (es) | Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias. | |
MX2019001210A (es) | Composicion farmaceutica anticancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |